CVE-2001-1077

Public Exploit

Description

Buffer overflow in tt_printf function of rxvt 2.6.2 allows local users to gain privileges via a long (1) -T or (2) -name argument.

4.6

CVSS

Severity: Medium

CVSS 2.0 •

EPSS 0.29%

Vendor Advisory linux-mandrake.com Vendor Advisory debian.org Vendor Advisory immunix.org Vendor Advisory securityfocus.com

Affected: n/a n/a

References

Link	Tags
http://www.securityfocus.com/bid/2878	vdb entry
http://www.linux-mandrake.com/en/security/2001/MDKSA-2001-060.php	vendor advisory
http://www.securityfocus.com/archive/1/191510	mailing list exploit patch vendor advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/6701	vdb entry
http://www.debian.org/security/2001/dsa-062	patch vendor advisory
http://download.immunix.org/ImmunixOS/7.0/updates/IMNX-2001-70-028-01	patch vendor advisory

Frequently Asked Questions

What is the severity of CVE-2001-1077?: CVE-2001-1077 has been scored as a medium severity vulnerability.
How to fix CVE-2001-1077?: To fix CVE-2001-1077, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2001-1077 being actively exploited in the wild?: It is possible that CVE-2001-1077 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.

This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.